# Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

> **NCT03793608** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 25 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT03793608
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-12
- **Primary completion:** 2021-02-19
- **Final completion:** 2021-05-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03793608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03793608, "Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03793608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*